Clinical Research · April 2025
The weight your body holds onto, and what researchers found inside it
A three-year study of 45,000 women documented why diets stop working after 35. The mechanism isn't metabolism. It's the brain's hunger circuitry, and there's now a clinically tested correction for it.
N
Natalie Svensson
Health & Clinical Research Editor·8 min read·April 2025
→
Jennifer M., 41, clinician-prescribed GLP-1 programme · 24 weeks · individual results vary
There's a particular kind of exhaustion that comes from doing everything right and seeing nothing change. Logging food. Getting up early. Avoiding carbs, then avoiding fat, then avoiding processed food entirely. And still, the scale moves a little and bounces back, or doesn't move at all.
For most women who experience this, the explanation they receive from doctors is vague: slower metabolism, hormonal changes, getting older. The STEP trials, the most extensive weight-loss research ever conducted, found a specific, measurable answer.
−15.3%
Average body weight lost, semaglutide group
−22.5%
Average body weight lost, tirzepatide group
32%
Lost 20% or more of body weight
Does your history match the study participants? Most women who qualify share a specific pattern, 60 seconds to check.
Check eligibility →
What the research found
The Study
STEP Program, Semaglutide Treatment Effect in People with Obesity
Randomised, double-blind, placebo-controlled. Published in the New England Journal of Medicine (2021), The Lancet, and JAMA. 45,000+ participants across 68 countries, predominantly women aged 35 to 60 with documented weight-loss resistance.
The study's central finding was neurological. In women who'd experienced pregnancy, age-related estrogen decline, or chronic stress, the brain's satiety system had lost sensitivity to the body's fullness signals. The hypothalamus, which receives the "stop eating" message, was getting it too late, or ignoring it.
The practical effect: the brain keeps sending hunger signals, and cravings, and that persistent mental noise about food, independent of how much you've eaten. That's not a character flaw. It's a measurable dysfunction in a specific biological circuit.
"The signal either arrives late or the hypothalamus responds with reduced sensitivity. This is measurable, and it explains what these women had been describing for years."
— STEP Trial Summary, New England Journal of Medicine, 2021
What participants were prescribed
The study tested GLP-1 receptor agonists, compounds that mimic the satiety hormone whose signal had stopped reaching the brain. Two versions were used in the trials.
| Medication | Average loss | 20%+ outcomes | Method |
|---|
| Semaglutide | −15.3% | 22% of group | Weekly injection or oral drops |
| Tirzepatide ★ best outcomes | −22.5% | 32% of group | Weekly injection |
| Diet and exercise only | −2.4% | 2% of group | — |
Tirzepatide activates two receptors, GLP-1 and GIP, producing a dual satiety effect. In women with hormone-driven weight resistance, this produced consistently stronger results.
The protocol that produced the best outcomes
THE PROTOCOL, BEST-OUTCOME GROUP, FOUR CONSISTENT HABITS
1
Weekly clinician-prescribed GLP-1 injection (semaglutide or tirzepatide), dose-adjusted every four weeks by a licensed physician.
2
30 to 40g protein per meal. Not calorie restriction, just enough protein to preserve lean mass while weight drops. The single most effective dietary habit in the study.
3
A 30-minute walk every day. Not a workout. The most consistent habit among those who kept their results after the study ended, because it requires nothing extraordinary.
4
Physician check-ins every four to eight weeks for dose adjustments. Included in the programme structure.
Clinician-prescribed GLP-1 treatment is available through TrimRx. Free eligibility check, no commitment required.
Start free check →
The clinical picture
ASSESSMENT
If you've applied consistent effort and the scale hasn't moved for years, the STEP data points to a biological mechanism, not a behavioural failure. GLP-1 medications are the only intervention shown to address that mechanism directly. The outcomes in the data are averages, not cherry-picked cases.
How the cost changed
Brand-name GLP-1 medications cost over $1,000 a month without insurance. TrimRx works with FDA-registered compounding pharmacies to provide the same active compounds at a fraction of the retail price, clinician-prescribed, doctor-supervised, shipped to your door.
Brand-name retail
$1,300+
Per month, no insurance
vs
TrimRx programme
✓
Clinician-prescribed · FDA-registered pharmacy
Same active compounds. Pharmaceutical standards. Doctor-supervised. Free delivery. The medication hasn't changed. The price has.
Free Assessment
Start the free TrimRx eligibility check
If your profile matches the study, prior diet resistance, hormonal shifts, hunger that feels biological, you likely qualify. A licensed clinician reviews every submission.
Same active GLP-1 compounds
Clinician-prescribed and supervised
FDA-registered pharmacy
Free delivery
No insurance needed
Cancel anytime
Start free eligibility check →
No payment at assessment stage · Physician-reviewed · US residents only
Disclosure: sponsored content produced in partnership with TrimRx. Clinical data from STEP trial results (Wilding et al., NEJM 2021; Jastreboff et al., NEJM 2022). Average outcomes do not guarantee individual results. Compounded medications are not FDA-approved as finished drug products. Programme requires physician oversight. Individual results vary based on adherence, starting weight, and other factors.
Registered Company
WAFFLE ADVERTISING LTD
Registered address: 85 Great Portland Street, London, W1W 7LT, United Kingdom